A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landsca ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...

Dr. Fouse expressed excitement about joining Madrigal and contributing to its mission, particularly following the launch of their first FDA-approved treatment for MASH, Rezdiffra. Appointment of ...

I look forward to working with her to drive the launch of Rezdiffra, expand geographically, advance our clinical program in compensated MASH cirrhosis, and build our pipeline. I’d also like to ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

The company’s medication, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and is currently being evaluated in a Phase 3 trial for ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, ...

The US regulator has cleared Madrigal’s oral THR β-selective agonist Rezdiffra (resmetirom) for adults with MASH – also known as non-alcoholic steatohepatitis (NASH) – who have moderate to ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

Analysts have suggested that the benefit of semaglutide is similar to that seen with Madrigal Pharma's Rezdiffra (resmetirom), currently the only FDA-approved therapy for MASH, which is also known ...